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Abstract. Absence of neoplastic disease in the organ-recipient 
is required in order to allow organ transplantation. Due to its 
rarity, no data regarding management of patients with Multiple 
endocrine neoplasia type 1 (MEN1) and end-stage renal 
failure candidates for kidney transplantation are available. 
A 36 year-old man was referred to the present hospital with 
MEN1, with a neuroendocrine pancreatic tumor and primary 
hyperparathyroidism and associated Alport syndrome with 
end stage renal failure. The present study aimed to establish 
the eligibility of the patient for a kidney transplantation. 
The neuroendocrine tumor had been treated with duodeno-
pancreatectomy two years earlier and hyperparathyroidism 
by parathyroidectomy. The review of the literature did not 
provide data regarding the eligibility for kidney transplanta-
tion of patients harboring a neuroendocrine pancreatic tumor 
in the context of MEN1. Due to the end-stage renal failure, 
neuroendocrine markers were unreliable and the investigation 
therefore relied on imaging studies, which were unremarkable. 
Young age, low-grade tumor, low expression of Ki67, absence 
of metastatic lymph nodes, onset in the setting of a MEN1 
were all positive prognostic factors of the neuroendocrine 
tumor. Normal serum calcium ruled out persistent primary 
hyperparathyroidism. Overall, hemodyalisis is known to 
significantly reduce life expectancy. Benefits of kidney 
transplantation overcome the risk of neuroendocrine tumor 
recurrence in a young patient bearing MEN1.
Introduction
Multiple endocrine neoplasia type 1 (MEN1), is a rare autosomal 
dominant disease, linked to a mutation of a tumor suppressor 
gene encoding for the protein menin. Tumors occur in para-
thyroids, pancreas and pituitary, with a variable phenotype. 
Alport syndrome, a recessive X-linked disease is due to muta-
tions of the genes, encoding for the procollagen IV, usually 
leading to end-stage chronic kidney disease. Neurosensory 
deafness, abnormally colored retina and misshapen lenses are 
the other most relevant features of the syndrome. The patient 
we describe herein was carrying both these rare diseases. The 
clinical challenge we had to face was to establish the eligibility 
of the patient to kidney and possibly pancreas transplantation.
Case report
We report on a 36 year-old man affected by MEN1, namely 
with primary hyperparathyroidism (PHPT) and non-secreting 
neuroendocrine pancreatic tumor and concomitant Alport 
syndrome with end-stage chronic kidney disease. At the age 
of 10, following the diagnosis of Alport syndrome in the 
mother's lineage, the patient underwent a kidney biopsy which 
showed a histologic picture of Alport syndrome. Five years 
later, because of increasing proteinuria, angiotensin converting 
enzyme inhibitor treatment was started. The renal function 
progressively deteriorated up to end-stage renal failure and, 
at the age of 32, hemodialysis was started. The diagnosis of 
Alport syndrome was confirmed by genetic analysis. Familial 
PHPT was diagnosed in his father's kindred when the patient 
was 30 year-old, and MEN1 genetic analysis revealed an 
uncommon complete deletion of the MEN gene in both the 
patient and his father. One year later, PHPT was also diag-
nosed in the patient who underwent surgical removal of the 
right superior, left superior and left inferior parathyroid glands. 
After surgery, cinacalcet therapy (30 mg/daily) was started. 
The patient was referred to our hospital for further evaluation. 
A whole-body CT scan, performed as part of the work out of 
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the MEN1 syndrome, showed multiple pancreatic lesions that 
were positive at the Gallium-68 Dotatoc PET scan (Fig. 1). 
Neuroendocrine markers were increased (Table I, column 1). 
However, treatment with proton pump inhibitor and end-stage 
renal failure lessened reliability of their measurement. In 2014, 
at the age of 32, the patient underwent duodenopancreatec-
tomy plus lymphadenectomy. Histology showed multiple foci 
of neuroendocrine tumors of intermediate grade (G2) wide-
spread in the pancreas, with vascular invasion, 2 mitosis/10 
high‑power fields, immunostaining positive for Ki67 (5%), 
chromogranin, CD56, insulin and negative for glucagon; no 
lymph nodes metastases were present (ENETS: pT2N0G2; 
AJCC: cT1N0M0). After duodenopancreatectomy, treatment 
with insulin for secondary diabetes was started. After recov-
ering from pancreatic surgery, in 2016, at the age of 36 years, 
the patient was evaluated for eligibility to kidney and possibly 
pancreas transplantation. At admission he was in good 
conditions. Daily treatment consisted of cinacalcet 30 mg, 
sevelamer 4,800 mg, lispro 30 IU, degludec 6 IU, pancreoli-
pase 60,000 IU, cardioaspirin 100 mg, esomeprazol 40 mg. 
Laboratory findings are shown in Table I (column 2). Neck 
ultrasound and tc-99m sestamibi scan showed a hyperplastic 
right inferior parathyroid (diameter: 20 mm). Abdominal CT 
scan, Gallium-68 Dotatoc PET scan and pituitary MRI were 
all unremarkable.
Discussion
MEN1, an autosomal dominant disease, presents with a low 
incidence (2-4/1,000,000 cases per year) but a very high 
penetrance. It is linked to a mutation of a tumor suppressor 
Table I. Laboratory findings before and after duodenopancreatectomy.
 Column 1 (before surgery) Column 2 (after surgery) Normal range
Glucose (mg/dl) 73 121a 74-109
Hemoglobin A1c (mmol/mol) NA 38a 20-38
Chromogranin A (ng/ml) 1680 NA <100
Neuron Specific Enolase (ng/ml) 17.6 12.3 <12.5
Glucagon (pg/ml) 1799 298 25-250
Gastrin (pg/ml) 255 NA 25-111
Histamine (mcmol/l) 10.6 NA <10
Calcium (mg/dl) 10.1b 8.6-9.7c 8.6-10.2
Phosphorus (mg/dl) 5.8 7.3 2.7-4.5
Albumin (g/dl) 4.58 4 3,5-5,5
PTH (pg/ml) 311b 248-283c 8-40
25 OH Vitamin D (ng/ml) 16.5 8.8 30-150
1-25 OH2 Vitamin D (pg/ml) NA 17 20-67
Bone Alkaline Phosphatase (mcg/l) 13 43 2-15
C-Terminal Telopeptide (ng/ml) >6 >6 0.115-0.748
Osteocalcin (ng/ml) >200 >200 6.8-34
ACTH (pg/ml) 31 NA 10-50
Cortisol (mcg/dl) 13.2 NA 6.7-22.6
IGF-1 (ng/ml) 166 NA 77-250
GH (ng/ml) 0.08 NA 0.01-3.6
FSH (mUI/ml) 5.7 NA 1.3-19.5
LH (mUI/ml) 4.9 NA 1.4-12.7
Testosteron (ng/ml) 2.7 NA 1.75-7.8
aAfter insulin treatment. bOn cinacalcet and c15 days after cinacalcet withdrawal. NA, not available.
Figure 1. 68-Ga-Dotatoc PET scan uptake of pancreatic neuroendocrine lesion.
MOLECULAR AND CLINICAL ONCOLOGY  8:  449-452,  2018 451
gene on the long arm (q) of chromosome 11 at position 13.1 
encoding for the protein menin. Tumors occur in parathyroids, 
pancreas and pituitary, with a variable phenotype. Alport 
syndrome, a recessive X-linked disease with an incidence of 
1/50,000 per year, is due to mutations of the COL4A3, A4 
and A5 genes, encoding for the procollagen IV. Neurosensory 
deafness, abnormally colored retina and misshapen lenses 
are the most relevant features of the syndrome. The patient 
we describe herein was carrying both these rare diseases. The 
clinical challenge we had to face was to establish the eligibility 
of the patient to kidney and possibly pancreas transplantation. 
To address this question we had to take into account several 
considerations, that will be addressed thereafter. It is gener-
ally agreed that only patients with no evidence of tumor are 
eligible to organ transplantation. We had therefore to establish 
that the neuroendocrine pancreatic tumor was on remission, 
on the basis of undetectable serum markers and negative 
imaging. Unfortunately, we could not rely on measurement of 
chromogranine because of coexistent modifiable (PPI treat-
ment) and non‑modifiable (end‑stage chronic kidney disease) 
interfering factors. Measurement of glucagon, which was 
very high before duodenopancreatectomy, was not informa-
tive for several reasons. Indeed, hyperglucagonemia can be 
observed in end stage renal failure (1), glucagon might have 
an extra-pancreatic origins and, in addition, the results of its 
measurement are often discordant (2). Older age, high-grade 
tumor, high expression of Ki67, number of metastatic lymph 
nodes and tumor-related symptoms are all negative prognostic 
factors for the recurrence of neuroendocrine tumors (3). Our 
patient was young and presented with a low/intermediate 
malignancy grade tumor with low grade of Ki67 expression. 
It has been reported that pancreatic neuroendocrine tumors 
in patients with MEN1 have a better prognosis compared 
to sporadic forms, even in case of recurrence (4). Moreover, 
because imaging studies were negative two years after duode-
nopancreatectomy, we concluded that the likelihood that the 
pancreatic tumor was on remission was high. The outcome 
of cancer in remission in patients undergoing organ trans-
plantation is uncertain. A recent meta-analysis of all-organ 
transplanted patients has shown a higher mortality rate (HR 
3.13; 95% CI, 2.29‑4.27) and a higher risk of other neoplasia 
(HR 1.92; 95% CI, 1.52‑2.42) in those cured from a concomi-
tant cancer than in transplanted, non-neoplastic patients (5). In 
keeping with their low prevalence, no data on the prevalence 
of neuroendocrine tumors in all-organ transplanted patients 
has been reported. Available data indicates that the recurrence 
rate of cancer in transplanted patients ranges between 5 and 
21%, and is strictly related to the lag between cancer remission 
and kidney transplantation as well as type of tumors, multiple 
myeloma, breast cancer and kidney cancer showing the higher 
recurrence rate (6). The suggested lag between cancer remis-
sion and eligibility to kidney transplantation varies according 
to the different guidelines and depends upon to the type of 
the tumor. No data about patients with neuroendocrine tumors 
undergoing kidney transplantation are currently available. One 
should also take in mind that the mortality rate, particularly 
because of cardiovascular complications, is higher in hemo-
dialyzed patients than in the general population. According 
to a recent report, the duration of hemodialysis influences 
the outcome of patients with end-stage kidney disease (7). 
Because our patient was on hemodialysis for 3 years, his life 
expectancy was reduced by 8‑20% (7). In addition, chronic 
kidney disease and dialysis are independent risk factors for the 
occurrence of new tumors (8), in particular lung and urinary 
tract cancer (9). We did not consider pancreatic transplantation 
as urgent as kidney transplantation because hyperglicemia was 
well managed by insulin treatment. In addition, compared to 
kidney transplantation, pancreatic transplantation requires a 
higher immunosuppressive treatment, which could negatively 
affect the outcome of the neuroendocrine pancreatic tumor. 
Immunosuppressive therapy by itself increases tumor inci-
dence and recurrences, the longer the treatment the higher the 
incidence of tumors (10). Finally, while establishing eligibility 
to kidney transplantation, we had to take into consideration 
the concomitant hyperparathyroidism. The finding of normal 
serum calcium and high PTH fifteen days after the with-
drawal of cinacalcet was in keeping with the end-stage renal 
disease and ruled out persistent primary hyperparathyroidism. 
Therefore an additional parathyroidectomy was not taken into 
consideration. In addition, post-surgical hypoparathyroidism 
usually worsens the adynamic bone state typical of uremic 
patients (11) and requires a strict adherence to medications to 
avoid hypocalcemia. We foresaw that a possible further rise in 
serum calcium would require a medical treatment in order to 
defer parathyroidectomy as long as possible. We concluded in 
favor of the eligibility of the patient for kidney transplantation 
for the following reasons: i) the remission of the pancreatic 
tumor ant its low risk of recurrence; ii) the higher mortality in 
end-stage renal failure overcomes the increased risk of recur-
rence of the pancreatic tumor after kidney transplantation; and 
iii) no evidence of hypercalcemia.
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